EHA Meeting 2026
At this year’s EHA Meeting, taking place 11–14 June 2026, in Stockholm, Sweden, we are proud to share new data and engage with the scientific community to drive progress in the care of people living with blood cancers.
You can see the conference program here:
Kite Publications:
| Title | Author List | Presentation information |
|---|---|---|
|
A Phase 1 Study of KITE-753 in Patients with R/R B‑cell Lymphoma: Updated Safety and Efficacy Results |
Saurabh Dahiya, Matthew Ulrickson, Jean Yared, Patrick M. Reagan, Timothy Voorhees, Andre Goy, Cameron J. Turtle, Lizama… |
Poster Session 2: Saturday, June 13, (18:45–19:45) CEST Abstract Code: PS2068 |
|
Anitocabtagene Autoleucel Clinical Trial Manufacturing Experience in Patients with R/R or Newly Diagnosed MM |
Krina Patel, Clare Spooner, Monique Giordana, Taryn Shuler, David Myers, Maria‑Victoria Mateos |
Abstract Code: PB3252 |
|
Axicabtagene Ciloleucel as Second-line Treatment in Patients with Late-relapsed LBCL: Interim Analysis of the LATE-R Clinical Trial from the Spanish Lymphoma Group GELTAMO |
Mariana Bastos-Oreiro, Armando López Guillermo, Javier Delgado, Izaskun Zeberio, Eva Gonzalez-Barca, Hugo Luzardo, Anton… |
Poster Session 1: Friday, June 12 (18:45–19:45 CEST) Abstract Code: PF981 |
|
Axicabtagene Ciloleucel for the Treatment of R/R DLBCL in Brazil: The Impact of CAR T-cell Therapy Wait Time and Treatment Sequencing |
João de Holanda Farias, Graeme Ball, Bradley Kievit, Rob Blissett, Jayr Schmidt |
Abstract Code: PB3720 |
|
Biologic Correlates of Long‑Term Response After Brexucabtagene Autoleucel Therapy in MCL: Product Phenotype, PK, and Baseline Features |
Sabina Adhikary, Kelly Speth, Colleen Schweitzer, Rhine Shen, Ioana Kloos, Marie José Kersten |
Poster Session 2: Saturday, June 13 (18:45–19:45 CEST) Abstract Code: PS2201 |
|
CAR T Cell Therapy in Clinical Routine: Quantification of Real-World Hospital Resource Use Across CAR T Care Pathway in Germany |
Katja Hesse, Isabell Kaufhold, Markus Finzsch, Florian Kron |
Poster Session 1: Friday, June 12 (18:45–19:45 CEST) Abstract Code: PF1415 |
|
Clinical and Economic Outcomes by Risk Group Among First-Line Patients with LBCL in the United States (US)-SEER-Medicare Data Analysis |
Yi Lin, Liana Nikolaenko, Elyse Swallow, Madhu Palivela, Jinlin Song, Markqayne Ray, Sakshi Sethi, David Cobley, Matthew… |
Abstract Code: PB3775 |
|
Cost-Effectiveness Analysis of Brexucabtagene Autoleucel in Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia in Singapore |
Esther Chan, Nurul A Abdul Halim, Tza Kai Diong, Emma New, Briana Tan, Francesca L.W.I. Lim |
Poster Session 2: Saturday, June 13 (18:45–19:45 CEST) Abstract Code: PS2513 |
|
Cost-Effectiveness of Axicabtagene Ciloleucel for Treating Taiwanese Patients with R/R DLBCL and High-Grade B-cell Lymphoma After First-Line Treatment |
Bor-Sheng Ko, Wen-Wen Yang, Yu-Chiao Wang, Diong Tza-Kai, Kuan-Der Lee, Raoh-Fang Pwu |
Poster Session 2: Saturday, June 13 (18:45–19:45 CEST) Abstract Code: PS2514 |
|
Cost-Effectiveness of Axicabtagene Ciloleucel in Taiwanese Patients with R/R DLBCL and Primary Mediastinal B-Cell Lymphoma After Two Lines of Systemic Therapy |
Kuan-Der Lee, Yu-Chiao Wang, Wen-Wen Yang, Diong Tza-Kai, Bor-Sheng Ko, Raoh-Fang Pwu |
Poster Session 1: Friday, June 12 (18:45–19:45 CEST) Abstract Code: PF1414 |
|
Exploring Global Variation in CAR T-Cell Therapy Practice Patterns for LBCL: Quantitative Research Findings |
Samuel Yamshon, Gloria Ines Iacoboni Garcia-Calvo, David Qualls, Ajay Major, Lizamarie Bachier-Rodriguez, Anna Maria Sur… |
Abstract Code: PB3712 |
|
Follow-Up Time–Adjusted Non-Relapse Mortality (NRM) in Patients With Non-Hodgkin Lymphoma Following CAR T-Cell Therapy Within Clinical Trials |
Michael Leisch, Thomas Melchardt, Guido Ghilardi, Caroline Arber, Ulrich Jäger, Normann Steiner, Björn Chapuy, Robin San… |
Poster Session 2: Saturday, June 13 (18:45–19:45 CEST) Abstract Code: PS2112 |
|
International Expert Consensus on Real-World CAR T-Cell Eligibility in LBCLs: An e-Delphi Study |
Catherine Thieblemont, Isabelle Fleury, Mazyar Shadman, Tobias A.W. Holderried, Graham Collins |
Poster Session 1: Friday, June 12 (18:45–19:45 CEST) Abstract Code: PF1023 |
|
Real-World Treatment Patterns and Survival Outcomes in Patients With Newly Diagnosed High-Risk LBCL |
Ran Reshef, Javier Munoz, Babatunde Adedokun, Qian Huang, Hil Hsu, Nan Liu, Madhu Palivela, Zhen-Huan Hu, Liana Nikolaen… |
Poster Session 1: Friday, June 12 (18:45–19:45 CEST) Abstract Code: PF1014 |
CAR, chimeric antigen receptor; DLBCL, diffuse large B-cell lymphoma; LBCL, large B-cell lymphoma; MCL, mantle cell lymphoma; (R/R) DLBCL, (relapse/refractory) diffuse large B-cell lymphoma.